Literature DB >> 11874235

Evidence that peroxynitrite affects human osteoblast proliferation and differentiation.

Francisco Airton Castro da Rocha1, Artur José de Brum-Fernandes.   

Abstract

Peroxynitrite (PN), a nitric oxide (NO*)-derived anion, has been associated with NO* damage in various cell types. We examined the effects of adding PN to cultured human osteoblast-like (hOB) cells obtained after hip arthroplasty. Exposure to PN (0.1-0.4 mM) decreased both hOB proliferation and differentiation, measured by [3H]thymidine uptake and alkaline phosphatase production, respectively. Incubation with 3-morpholinosydnonimine (SIN-1; 0.25-1 mM), an NO* and O2- donor that leads to PN release, also reduced both hOB proliferation and differentiation. Coincubation with both superoxide dismutase (SOD; 100 U/ml) and catalase (CAT; 50 U/ml), rendering SIN-1 a pure NO* donor, reversed its effects on hOB proliferation and differentiation. However, SIN-1-induced NO* production, measured by nitrite release to the hOB medium, was not altered by cotreatment with SOD and CAT. Expression of nitrotyrosine by hOB, a marker of PN action, was significantly increased after SIN-1 addition, as compared with untreated cells, as revealed by Western blot analysis. Interleukin-1alpha (IL-1alpha) and interferon gamma (IFN-gamma) but not tumor necrosis factor alpha (TNF-alpha) also significantly increased nitrotyrosine expression in these cells. These data show that PN is at least partially responsible for osteoblast derangement by NO* and that cytokines released during inflammatory arthropathies can induce PN production in hOB cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874235     DOI: 10.1359/jbmr.2002.17.3.434

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Neutrophils-derived peroxynitrite contributes to acute hyperalgesia and cell influx in zymosan arthritis.

Authors:  Mirna M Bezerra; Susan D Brain; Virgínia C C Girão; Stan Greenacre; Julie Keeble; Francisco A C Rocha
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-12-15       Impact factor: 3.000

2.  Tadalafil analgesia in experimental arthritis involves suppression of intra-articular TNF release.

Authors:  F A C Rocha; F S Silva; A C R M Leite; A K R M Leite; V C C Girão; R R Castro; F Q Cunha
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  Reactive nitrogen species scavenging, rather than nitric oxide inhibition, protects from articular cartilage damage in rat zymosan-induced arthritis.

Authors:  Mirna Marques Bezerra; Susan D Brain; Stan Greenacre; Selma Maria Bezerra Jerônimo; Liana Batista de Melo; Julie Keeble; Francisco Airton Castro da Rocha
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

4.  Protective effect of an extract from Ascaris suum in experimental arthritis models.

Authors:  Francisco Airton Castro Rocha; Ana Karine Rocha Melo Leite; Margarida Maria Lima Pompeu; Thiago Mattar Cunha; Waldiceu A Verri; Fernanda Macedo Soares; Rondinelle Ribeiro Castro; Fernando Queiroz Cunha
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

5.  Molecular Mechanism of Silver Nanoparticles-Induced Human Osteoblast Cell Death: Protective Effect of Inducible Nitric Oxide Synthase Inhibitor.

Authors:  Ewelina Zielinska; Cecylia Tukaj; Marek Witold Radomski; Iwona Inkielewicz-Stepniak
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

Review 6.  The Paradoxical Role of Uric Acid in Osteoporosis.

Authors:  Kun-Mo Lin; Chien-Lin Lu; Kuo-Chin Hung; Pei-Chen Wu; Chi-Feng Pan; Chih-Jen Wu; Ren-Si Syu; Jin-Shuen Chen; Po-Jen Hsiao; Kuo-Cheng Lu
Journal:  Nutrients       Date:  2019-09-05       Impact factor: 5.717

7.  Cell sources of inflammatory mediators present in bone marrow areas inside the meniscus.

Authors:  Francisco Airton Castro Rocha; Virgínia Claudia Carneiro Girão; Rodolfo de Melo Nunes; Ana Carolina Matias Dinelly Pinto; Bruno Vidal; João Eurico Fonseca
Journal:  PLoS One       Date:  2019-12-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.